Association of ionizing radiation dose from common medical diagnostic procedures and lymphoma risk in the Epilymph case-control study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 01 03 2019
accepted: 21 06 2020
entrez: 11 7 2020
pubmed: 11 7 2020
medline: 17 9 2020
Statut: epublish

Résumé

Medical diagnostic X-rays are an important source of ionizing radiation (IR) exposure in the general population; however, it is unclear if the resulting low patient doses increase lymphoma risk. We examined the association between lifetime medical diagnostic X-ray dose and lymphoma risk, taking into account potential confounding factors, including medical history. The international Epilymph study (conducted in the Czech-Republic, France, Germany, Ireland, Italy, and Spain) collected self-reported information on common diagnostic X-ray procedures from 2,362 lymphoma cases and 2,465 frequency-matched (age, sex, country) controls. Individual lifetime cumulative bone marrow (BM) dose was estimated using time period-based dose estimates for different procedures and body parts. The association between categories of BM dose and lymphoma risk was examined using unconditional logistic regression models adjusting for matching factors, socioeconomic variables, and the presence of underlying medical conditions (atopic, autoimmune, infectious diseases, osteoarthritis, having had a sick childhood, and family history of lymphoma) as potential confounders of the association. Cumulative BM dose was low (median 2.25 mGy) and was not positively associated with lymphoma risk. Odds ratios (ORs) were consistently less than 1.0 in all dose categories compared to the reference category (less than 1 mGy). Results were similar after adjustment for potential confounding factors, when using different exposure scenarios, and in analyses by lymphoma subtype and by type of control (hospital-, population-based). Overall no increased risk of lymphoma was observed. The reduced ORs may be related to unmeasured confounding or other sources of systematic bias.We found little evidence that chronic medical conditions confound lymphoma risk and medical radiation associations.

Identifiants

pubmed: 32649712
doi: 10.1371/journal.pone.0235658
pii: PONE-D-19-06055
pmc: PMC7351167
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0235658

Commentaires et corrections

Type : ErratumIn

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Environ Health Perspect. 2005 Jan;113(1):1-5
pubmed: 15626639
Radiat Res. 2012 Mar;177(3):229-43
pubmed: 22171960
Phys Med Biol. 1981 May;26(3):389-400
pubmed: 7243876
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1105-13
pubmed: 27197296
Radiat Res. 2007 Apr;167(4):361-79
pubmed: 17388694
Int J Cancer. 2007 Oct 15;121(8):1806-12
pubmed: 17557295
Eur J Epidemiol. 2018 Apr;33(4):393-401
pubmed: 29349586
Sci Rep. 2016 Oct 17;6:35181
pubmed: 27748377
Br J Radiol. 2006 Jan;79(937):5-8
pubmed: 16421398
Health Phys. 2009 Jul;97(1):1-5
pubmed: 19509507
Health Phys. 2020 Feb;118(2):136-148
pubmed: 31634260
Br J Cancer. 2011 Apr 26;104(9):1482-6
pubmed: 21522150
Radiology. 2009 Nov;253(2):520-31
pubmed: 19789227
Cancer Res. 1992 Oct 1;52(19 Suppl):5489s-5491s
pubmed: 1394160
J Natl Cancer Inst Monogr. 2014 Aug;2014(48):130-44
pubmed: 25174034
Am J Epidemiol. 2003 Apr 1;157(7):652-63
pubmed: 12672685
Environ Health Perspect. 2013 Jan;121(1):59-65
pubmed: 23149165
Pediatr Radiol. 2016 Jan;46(1):119-29
pubmed: 26276264
Am J Epidemiol. 1990 Oct;132(4):746-8
pubmed: 2403115
Radiat Prot Dosimetry. 2012 Jul;150(4):415-26
pubmed: 22228685
Radiat Res. 2007 Feb;167(2):222-32
pubmed: 17390730
Radiat Res. 2008 Dec;170(6):721-35
pubmed: 19138033
Br J Radiol. 2016;89(1060):20150305
pubmed: 26864156
J Radiol Prot. 2011 Sep;31(3):329-35
pubmed: 21865611
Int J Epidemiol. 2005 Jun;34(3):680-7
pubmed: 15802377
Lancet Haematol. 2015 Jul;2(7):e276-81
pubmed: 26436129
J Cancer Epidemiol. 2012;2012:978930
pubmed: 23008714
Cancer Epidemiol Biomarkers Prev. 2017 May;26(5):804-806
pubmed: 28052939
Radiat Res. 2013 Mar;179(3):361-82
pubmed: 23398354
JAMA. 1991 Mar 13;265(10):1290-4
pubmed: 2053936
Health Phys. 2003 Feb;84(2):245-59
pubmed: 12553655
Environ Health Perspect. 2006 Jun;114(6):818-22
pubmed: 16759978
Am J Epidemiol. 2009 Apr 15;169(8):969-76
pubmed: 19270049
Leuk Res. 2007 Oct;31(10):1365-72
pubmed: 17481729
BMC Health Serv Res. 2012 Jan 27;12:24
pubmed: 22283843
J Cancer Res Clin Oncol. 2009 Aug;135(8):1099-107
pubmed: 19205736
Radiat Res. 2015 Dec;184(6):595-610
pubmed: 26579944
BMC Res Notes. 2015 Jul 10;8:300
pubmed: 26159425
BMJ. 2013 May 21;346:f2360
pubmed: 23694687

Auteurs

Elisa Pasqual (E)

Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Barcelona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Michelle C Turner (MC)

Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Barcelona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, Canada.

Esther Gracia-Lavedan (E)

Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Barcelona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Delphine Casabonne (D)

CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Barcelona, Spain.

Yolanda Benavente (Y)

CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Barcelona, Spain.

Isabelle Thierry Chef (IT)

Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Barcelona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Marc Maynadié (M)

Registre des Hémopathies Malignes de Côte d'Or INSERM U 1231, Université de Bourgogne Franche-Comté et CHU Dijon-Bourgogne, Dijon, France.

Pierluigi Cocco (P)

Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Cagliari, Italy.

Anthony Staines (A)

School of Nursing and Human Science, Dublin City University, Glasnevin, Dublin, Ireland.

Lenka Foretova (L)

Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute and MF MU, Brno, Czech Republic.

Alexandra Nieters (A)

Centre of Chronic Immunodeficiency, Molecular Epidemiology, University Medical Center Freiburg, Freiburg, Germany.

Paolo Boffetta (P)

Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.

Paul Brennan (P)

IARC, International Agency for Research on Cancer, Lyon, France.

Elisabeth Cardis (E)

Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Barcelona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Silvia de Sanjose (S)

CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH